에 대한 최신 뉴스 Amgen (NASDAQ:AMGN) 주식

Amgen

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ABBV

AMGN

시장이 불안정하고 혼란스러운 시기에는 많은 투자자들이 배당 수익률이 높은 주식으로 눈을 돌립니다. 이러한 주식은 높은 자유 현금 흐름을 가지고 있으며 주주들에게 높은 배당금을 지급하여 보상을 합니다.

Benzinga 독자들은 애널리스트 주식 등급 페이지를 방문하여 자신이 선호하는 주식에 대한 최신 애널리스트 의견을 검토할 수 있습니다. 트레이더들은 Benzinga의 방대한 애널리스트 등급

월가에서 가장 정확한 분석가들이 주목: 고배당 수익을 창출하는 3개의 헬스케어 주식

AMZN

CSCO

SPDR Dow Jones Industrial Average ETF Trust

NVDA

주식과 옵션을 볼 때 투자자들은 섹터 회전, 실적 강세, 다가오는 촉매제 등 여러 가지 전략을 사용한다. 가치 투자자들은 종종 배당주에서 강력한 실적 강세를 찾는다. 다우존스 산업평균지수에는 배당금을 지급하는 주식이 많이 포함되어 있으며, 꾸준히 배당금을 인상해 온 블루칩 기업들이 많다.

2025년 최대 6.8% 배당을 제공하는 고배당 주식 10선: 다우 지수의 주식

Biotech

Specialty ETFs

Health Care

Politics

ETFs

General

SCHD

슈왑 미국 배당주 ETF(NYSE:SCHD)는 12월에 7% 이상 하락하면서 지난 한 달 동안 1년간 상승폭의 절반 이상을 반납했다. SCHD 펀드가 하락한 이유를 살펴보자.

슈왑 미국 배당주 ETF(SCHD), 12월에 7% 이상 하락한 이유는?

Amgen Inc

CNBC Halftime Report Final Trades: Amgen, Prologis, 3M Company, Visa

Live On CNBC, Rob Sechan Announces Bought More Amgen

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$48.00</td>
<td>$81.9K</td>
<td>541</td>
<td align="right">474</td>
</tr>
<tr>
<td>MDGL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$380.00</td>
<td>$74.5K</td>
<td>42</td>
<td align="right">88</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$295.00</td>
<td>$34.6K</td>
<td>148</td>
<td align="right">31</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$20.00</td>
<td>$26.3K</td>
<td>2.6K</td>
<td align="right">26</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$110.00</td>
<td>$25.4K</td>
<td>86</td>
<td align="right">25</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$300.00</td>
<td>$91.7K</td>
<td>3</td>
<td align="right">15</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$960.00</td>
<td>$120.4K</td>
<td>79</td>
<td align="right">10</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$480.00</td>
<td>$27.2K</td>
<td>1.1K</td>
<td align="right">9</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$280.00</td>
<td>$32.2K</td>
<td>2</td>
<td align="right">6</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$590.00</td>
<td>$26.2K</td>
<td>7</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with neutral sentiment. It expires in 50 day(s) on April 17, 2025. Parties traded 200 contract(s) at a $48.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $81.9K, with a price of $410.0 per contract. There were 541 open contracts at this strike prior to today, and today 474 contract(s) were bought and sold. 
• For MDGL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>), we notice a call option sweep that happens to be bearish, expiring in 50 day(s) on April 17, 2025. This event was a transfer of 25 contract(s) at a $380.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $74.5K, with a price of $2970.0 per contract. There were 42 open contracts at this strike prior to today, and today 88 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a call option sweep that happens to be neutral, expiring in 2 day(s) on February 28, 2025. This event was a transfer of 25 contract(s) at a $295.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $34.6K, with a price of $1387.0 per contract. There were 148 open contracts at this strike prior to today, and today 31 contract(s) were bought and sold. 
• For TGTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>), we notice a call option trade that happens to be neutral, expiring in 324 day(s) on January 16, 2026. This event was a transfer of 20 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $26.3K, with a price of $1315.0 per contract. There were 2612 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a call option trade with neutral sentiment. It expires in 79 day(s) on May 16, 2025. Parties traded 25 contract(s) at a $110.00 strike. The total cost received by the writing party (or parties) was $25.4K, with a price of $1020.0 per contract. There were 86 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold. 
• Regarding VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we observe a call option trade with neutral sentiment. It expires in 2 day(s) on February 28, 2025. Parties traded 5 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $91.7K, with a price of $18346.0 per contract. There were 3 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a put option trade with bearish sentiment. It expires in 324 day(s) on January 16, 2026. Parties traded 10 contract(s) at a $960.00 strike. The total cost received by the writing party (or parties) was $120.4K, with a price of $12040.0 per contract. There were 79 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option sweep with bullish sentiment. It expires in 324 day(s) on January 16, 2026. Parties traded 5 contract(s) at a $480.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $27.2K, with a price of $5455.0 per contract. There were 1141 open contracts at this strike prior to today, and today 9 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a put option sweep with bearish sentiment. It expires in 387 day(s) on March 20, 2026. Parties traded 6 contract(s) at a $280.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $32.2K, with a price of $5383.0 per contract. There were 2 open contracts at this strike prior to today, and today 6 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a put option trade that happens to be bullish, expiring in 688 day(s) on January 15, 2027. This event was a transfer of 5 contract(s) at a $590.00 strike. The total cost received by the writing party (or parties) was $26.2K, with a price of $5258.0 per contract. There were 7 open contracts at this strike prior to today, and today 0 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MDGL

SRPT

TGTX

VRTX

10 Health Care Stocks Whale Activity In Today's Session

Legal

VKTX

Drug Compounders Sue U.S. Drug Regulator Over Removal Of Novo Nordisk Diabetes, Weight Loss Drugs From Shortage List

Revealing a significant insider sell on February 21, Derek Miller, SVP at Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), as per the latest SEC filing.
What Happened: Miller's decision to sell 2,024 shares of Amgen was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000318154/000112760225006112//Archives/edgar/data/318154/000112760225006112/0001127602-25-006112-index.htm">U.S. Securities and Exchange Commission</a> on Friday. The total value of the sale is $593,933.
Monitoring the market, Amgen's shares up by 0.2% at $298.52 during Friday's morning.
<h3>Unveiling the Story Behind Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Understanding the Numbers: Amgen's Finances</h3>
Revenue Growth: Amgen's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 10.86%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 65.75%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Amgen's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 1.17.
</li>
</ul>
Debt Management: Amgen's debt-to-equity ratio stands notably higher than the industry average, reaching 10.23. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 39.41 is lower than the industry average, implying a discounted valuation for Amgen's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 4.82, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 15.59 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000318154">Check Out The Full List Of Amgen's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Derek Miller Takes Money Off The Table, Sells $593K In Amgen Stock

DRIO

LFVN

RHHBY

TERN

VANI

FDA Says Novo Nordisk's Ozempic Injection .68 mg/1 ml, Injection 1.34 mg/1 ml, Injection 2.68 Mg/1 ml Available As Of Feb 21; Novo Nordisk's Wegovy, Injection, 1.7 mg/.75 ml , Wegovy, Injection, 2.4 mg/.75 ml Now Available; FDA Says Semaglutide Injection Shortage Is Resolved As Of Feb 21

Amgen's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NYSE">AMGN</a>) short percent of float has risen 11.27% since its last report. The company recently reported that it has 12.74 million shares sold short, which is 2.37% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.31 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Amgen Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739982618_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Amgen has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Amgen's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Amgen's peer group average for short interest as a percentage of float is 5.26%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Amgen's Recent Short Interest

It was reported on February 14, that Murdo Gordon, EVP at Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) executed a significant insider sell, according to an SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000318154/000112760225004776//Archives/edgar/data/318154/000112760225004776/0001127602-25-004776-index.htm">U.S. Securities and Exchange Commission</a> on Friday outlined that Gordon executed a sale of 8,771 shares of Amgen with a total value of $2,585,644.
Tracking the Friday's morning session, Amgen shares are trading at $293.93, showing a down of 1.02%.
<h3>Unveiling the Story Behind Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Amgen's Financial Performance</h3>
Revenue Growth: Amgen displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 23.18%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: With a low gross margin of 61.07%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Amgen's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 5.27.
</li>
</ul>
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 8.02, caution is advised due to increased financial risk.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 39.28 is lower than the industry average, implying a discounted valuation for Amgen's stock.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 4.81 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 26.76 reflects market recognition of Amgen's value, positioning it as more highly valued compared to industry peers.
</li>
</ul>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000318154">Check Out The Full List Of Amgen's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EVP At Amgen Sells $2.59M Of Stock

Deep-pocketed investors have adopted a bearish approach towards Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMGN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Amgen. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 66% bearish. Among these notable options, 6 are puts, totaling $210,150, and 3 are calls, amounting to $161,431.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $280.0 to $305.0 for Amgen over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 448.17 with a total volume of 924.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $280.0 to $305.0 over the last 30 days.
<h3>Amgen Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739391322_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.45</td>
<td>$3.25</td>
<td>$3.45</td>
<td>$305.00</td>
<td>$107.2K</td>
<td align="right">318</td>
<td align="right">408</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.0</td>
<td>$8.35</td>
<td>$9.0</td>
<td>$300.00</td>
<td>$47.7K</td>
<td align="right">344</td>
<td align="right">53</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.0</td>
<td>$8.95</td>
<td>$9.0</td>
<td>$300.00</td>
<td>$42.3K</td>
<td align="right">344</td>
<td align="right">100</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$13.5</td>
<td>$13.35</td>
<td>$13.5</td>
<td>$290.00</td>
<td>$33.7K</td>
<td align="right">675</td>
<td align="right">54</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$13.65</td>
<td>$13.45</td>
<td>$13.5</td>
<td>$290.00</td>
<td>$31.0K</td>
<td align="right">675</td>
<td align="right">85</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Having examined the options trading patterns of Amgen, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Amgen</h3>
<ul>
<li>With a volume of 1,356,099, the price of AMGN is down -0.63% at $294.81. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 78 days.</li>
</ul>
<h3>What Analysts Are Saying About Amgen</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $305.75.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Underperform rating for Amgen, targeting a price of $275. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Amgen with a target price of $295. 
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $324. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Amgen, maintaining a target price of $329. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amgen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Amgen Unusual Options Activity For February 12

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$75.00</td>
<td>$39.4K</td>
<td>2.1K</td>
<td>8.1K</td>
</tr>
<tr>
<td>AHCO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$10.00</td>
<td>$71.4K</td>
<td>0</td>
<td>4.7K</td>
</tr>
<tr>
<td>THC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$145.00</td>
<td>$105.8K</td>
<td>1.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>COR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$230.00</td>
<td>$822.5K</td>
<td>495</td>
<td>258</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$35.00</td>
<td>$81.1K</td>
<td>5.1K</td>
<td>217</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$270.00</td>
<td>$140.0K</td>
<td>355</td>
<td>200</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$390.00</td>
<td>$39.6K</td>
<td>484</td>
<td>151</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$610.00</td>
<td>$53.0K</td>
<td>100</td>
<td>137</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$67.50</td>
<td>$33.6K</td>
<td>1.8K</td>
<td>120</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$860.00</td>
<td>$25.3K</td>
<td>50</td>
<td>112</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be bearish, expiring in 3 day(s) on February 14, 2025. This event was a transfer of 200 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $39.4K, with a price of $197.0 per contract. There were 2192 open contracts at this strike prior to today, and today 8123 contract(s) were bought and sold. 
• Regarding AHCO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>), we observe a put option sweep with bearish sentiment. It expires in 220 day(s) on September 19, 2025. Parties traded 476 contract(s) at a $10.00 strike. This particular put needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $71.4K, with a price of $150.0 per contract. There were 0 open contracts at this strike prior to today, and today 4752 contract(s) were bought and sold. 
• For THC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), we notice a call option sweep that happens to be neutral, expiring in 10 day(s) on February 21, 2025. This event was a transfer of 300 contract(s) at a $145.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $105.8K, with a price of $355.0 per contract. There were 1108 open contracts at this strike prior to today, and today 1040 contract(s) were bought and sold. 
• Regarding COR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), we observe a call option trade with bearish sentiment. It expires in 339 day(s) on January 16, 2026. Parties traded 250 contract(s) at a $230.00 strike. The total cost received by the writing party (or parties) was $822.5K, with a price of $3290.0 per contract. There were 495 open contracts at this strike prior to today, and today 258 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a call option sweep with bullish sentiment. It expires in 339 day(s) on January 16, 2026. Parties traded 100 contract(s) at a $35.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $81.1K, with a price of $812.0 per contract. There were 5109 open contracts at this strike prior to today, and today 217 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a put option trade that happens to be bullish, expiring in 129 day(s) on June 20, 2025. This event was a transfer of 200 contract(s) at a $270.00 strike. The total cost received by the writing party (or parties) was $140.0K, with a price of $700.0 per contract. There were 355 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 10 day(s) on February 21, 2025. This event was a transfer of 99 contract(s) at a $390.00 strike. This particular put needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $39.6K, with a price of $400.0 per contract. There were 484 open contracts at this strike prior to today, and today 151 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a call option sweep that happens to be bullish, expiring in 17 day(s) on February 28, 2025. This event was a transfer of 53 contract(s) at a $610.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $53.0K, with a price of $1000.0 per contract. There were 100 open contracts at this strike prior to today, and today 137 contract(s) were bought and sold. 
• Regarding AZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), we observe a call option sweep with bearish sentiment. It expires in 65 day(s) on April 17, 2025. Parties traded 57 contract(s) at a $67.50 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $33.6K, with a price of $590.0 per contract. There were 1841 open contracts at this strike prior to today, and today 120 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option trade that happens to be bearish, expiring in 157 day(s) on July 18, 2025. This event was a transfer of 4 contract(s) at a $860.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $6340.0 per contract. There were 50 open contracts at this strike prior to today, and today 112 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AHCO

MRNA

10 Health Care Stocks With Whale Alerts In Today's Session

Piper Sandler analyst David Amsellem maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Overweight and raises the price target from $310 to $329.

Piper Sandler Maintains Overweight on Amgen, Raises Price Target to $329

A substantial insider sell was reported on February 7, by Nancy A Grygiel, SVP &amp; CCO at Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), based on the recent SEC filing.
What Happened: Grygiel's recent move involves selling 1,589 shares of Amgen. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000318154/000112760225003500//Archives/edgar/data/318154/000112760225003500/0001127602-25-003500-index.htm">U.S. Securities and Exchange Commission</a> on Friday. The total value is $483,807.
Amgen shares are trading down 0.11% at $297.45 at the time of this writing on Friday morning.
<h3>Discovering Amgen: A Closer Look</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Amgen: Delving into Financials</h3>
Revenue Growth: Over the 3 months period, Amgen showcased positive performance, achieving a revenue growth rate of 23.18% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 61.07%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Amgen's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 5.27.
</li>
</ul>
Debt Management: Amgen's debt-to-equity ratio stands notably higher than the industry average, reaching 8.02. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Amgen's P/E ratio of 39.39 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 4.82 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Amgen's EV/EBITDA ratio of 26.82 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000318154">Check Out The Full List Of Amgen's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Nancy A Grygiel Implements A Sell Strategy: Offloads $483K In Amgen Stock

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group raised Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) price target from $176 to $202. Evercore ISI Group analyst Mark Lipacis maintained an Outperform rating. Arm shares closed at $173.26 on Wednesday. <a href="https://www.benzinga.com/quote/ARM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised the price target for Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) from $256 to $275. B of A Securities analyst Tim Anderson maintained an Underperform rating. Amgen shares closed at $307.81 on Wednesday. <a href="https://www.benzinga.com/quote/AMGN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital boosted Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) price target from $233 to $260. BMO Capital analyst Rufus Hone maintained an Outperform rating. Fiserv shares closed at $229.53 on Wednesday. <a href="https://www.benzinga.com/quote/FI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised the price target for Coherent Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) from $105 to $115. Rosenblatt analyst Mike Genovese maintained a Neutral rating. Coherent shares closed at $90.10 on Wednesday. <a href="https://www.benzinga.com/quote/COHR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Northland Capital Markets cut the price target for CSG Systems International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGS#NASDAQ">CSGS</a>) from $78 to $80. Northland Capital Markets analyst Nehal Chokshi reiterated an Outperform rating. CSG Systems shares closed at $61.66 on Wednesday. S<a href="https://www.benzinga.com/quote/CSGS/analyst-ratings">ee how other analysts view this stoc</a>k.</li>
<li>Piper Sandler slashed Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) price target from $85 to $70. Piper Sandler analyst Harsh Kumar maintained a Neutral rating. Skyworks shares settled at $87.08 on Wednesday. <a href="https://www.benzinga.com/quote/SWKS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) price target from $158 to $153. Barclays analyst Lauren Lieberman maintained an Overweight rating. PepsiCo shares closed at $145.66 on Wednesday. <a href="https://www.benzinga.com/quote/PEP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners cut Hologic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) price target from $80 to $75. Leerink Partners analyst Puneet Souda downgraded the stock from Outperform to Market Perform. Hologic shares closed at $72.80 on Wednesday.  <a href="https://www.benzinga.com/quote/HOLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs raised the price target for Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) from $300 to $310. Goldman Sachs analyst Kash Rangan maintained a Buy rating. Workday shares settled at $276.17 on Wednesday. <a href="https://www.benzinga.com/quote/WDAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler slashed Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) price target from $82 to $80. Piper Sandler analyst Thomas Champion maintained an Overweight rating. Uber shares closed at $64.48 on Wednesday. <a href="https://www.benzinga.com/quote/UBER/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43493237/jim-cramer-this-health-care-stock-is-a-winner-buy-bitcoin-instead-of-coinbase">Jim Cramer: This Health Care Stock Is A &#8216;Winner,&#8217; Buy Bitcoin Instead Of Coinbase</a></li>
</ul>

COHR

CSGS

HOLX

SWKS

UBER

WDAY

Uber To $80? Here Are 10 Top Analyst Forecasts For Thursday

B of A Securities analyst Tim Anderson maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Underperform and raises the price target from $256 to $275.

B of A Securities Maintains Underperform on Amgen, Raises Price Target to $275

Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from <a href="https://www.benzinga.com/25/02/43494246/private-employment-rises-by-183000-beats-estimates-in-january-consumer-facing-industries-drove-hiring">positive labor market data.</a>
The S&amp;P 500 gained 0.3% to 6,045 points, while the Dow Jones Industrial Average rose 0.6%, now trading less than 1% below its all-time high.
Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) missed quarterly earnings expectations on its cloud business, triggering a 7% drop, its worst single-day decline in a year. On the upside, Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) surged 6% after beating estimates, fueling a rally in chip stocks. Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) also gained 3.4%.
The Russell 2000 outperformed with a 0.9% gain, reflecting strength in smaller-cap stocks.
Fresh labor market data signaled resilience. Private sector employment rose by 183,000 in January according to the ADP report, surpassing expectations of 150,000. The services sector continued expanding,<a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43499292/us-services-growth-slows-in-january-as-tariff-concerns-mount"> as per ISM survey</a>, though at a slightly slower-than-anticipated pace.
Investors piled into Treasuries, sending yields tumbling across the curve. The 30-year yield fell to its lowest level since Dec. 18, 2024, while the iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) rallied 1.9%.
Gold extended its bull run, surging over 1% to a record $2,870 per ounce, driven by continued central bank buying. Copper jumped 2%. 
In crypto markets, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) edged down 1.2% to $97,000. 
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>• Russell 2000</td>
<td>2,310.94</td>
<td>0.9%</td>
</tr>
<tr>
<td>• Dow Jones</td>
<td>44,801.97</td>
<td>0.6%</td>
</tr>
<tr>
<td>• S&amp;P 500</td>
<td>6,054.99</td>
<td>0.3%</td>
</tr>
<tr>
<td>• Nasdaq 100</td>
<td>21,621.68</td>
<td>0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 2:00 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;rose 0.3% to $602.97.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.5% to $447.60.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;inched 0.2% up to $525.63.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 1% to $229.09.</li>
<li>The&nbsp;Real Estate Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) outperformed, up 1.6%; the&nbsp;Communication Services Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) lagged, down 1.2%.</li>
</ul>
<h3 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h3>
Stocks reacting on earnings reports included: 
<ul>
<li>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>): up 5.9%</li>
<li>Chipotle Mexican Grill Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>): down 2.4%</li>
<li>Mondelez International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>): up 0.62%</li>
<li>Simon Property Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>): 3.55%</li>
<li>Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>): up 5.7%</li>
<li>Snap Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NASDAQ">SNAP</a>): down 6.55%</li>
<li>IDEX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEX#NYSE">IEX</a>): down 9.61%</li>
<li>Walt Disney Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>): down 1.77%</li>
<li>Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>): down 7.31%</li>
<li>Fiserv Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>): up 7.48%</li>
<li>Boston Scientific Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>): up 1.87%</li>
<li>Illinois Tool Works Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>): down 0.62%</li>
<li>Emerson Electric Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>): down 2.61%</li>
<li>T. Rowe Price Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>): down 3.91%</li>
<li>Cencora Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>): up 0.83%</li>
<li>CDW Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>): up 4.54%</li>
<li>Ares Management Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>): down 2.51%</li>
<li>Bunge Global SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>): down 5.05%</li>
<li>Johnson Controls International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>): up 12.49%</li>
<li>Old Dominion Freight Line Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>): up 5.60%</li>
<li>Stanley Black &amp; Decker Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>): down 1.43%</li>
<li>Ares Capital Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>): down 3.26%</li>
<li>Criteo SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>): up 17.73%</li>
<li>Timken Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKR#NYSE">TKR</a>): up 2.86%</li>
<li>Performance Food Group Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>): down 1.91%</li>
<li>New York Times Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYT#NYSE">NYT</a>): down 11.56%</li>
<li>Griffon Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFF#NYSE">GFF</a>): up 9.00%</li>
<li>Harley-Davidson Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOG#NYSE">HOG</a>): down 0.63%</li>
<li>Capri Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>): down 13.94%</li>
<li>Azenta Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZTA#NASDAQ">AZTA</a>): up 1.04%</li>
<li>Vishay Intertechnology Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSH#NYSE">VSH</a>): up 8.65%</li>
<li>Spire Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>): up 0.82%</li>
</ul>
Large-cap stocks slated to report earnings after the close are Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), McKesson Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), O&#8217;Reilly Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>), MetLife Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>), Cognizant Technology Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>), Corteva Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>), Allstate Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>), Skyworks Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>), Aflac Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>), Align Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>). 
Read now: 
<ul>
<li><a href="https://www.benzinga.com/news/25/02/43503385/trumps-gaza-plan-for-seaside-resort-faces-global-pushback">Trump&#8217;s Plan To Turn Gaza Into Seaside Resort, Remove 2 Million Palestinians Roundly Rejected By World Leaders</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Macro Economic Events

Sector ETFs

Bonds

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Tech

$BTC

ALGN

ARCC

ARES

AVGO

AZTA

CMRE

CPRI

CRTO

CTSH

CTVA

GOOGL

MDLZ

ODFL

ORLY

PFGC

QCOM

REYN

RSVR

SNAP

TECH

iShares Trust Barclays 20+ Year Treasury Bond Fund

TROW

XLRE

Stocks Rebound, Google Eyes Worst Drop In A Year, Gold Shatters Fresh Records: What's Driving Markets Wednesday?

On Tuesday, Amgen&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) reported fourth-quarter sales of $9.10 billion, up 11% year-over-year, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $8.9 billion</a>.
<ul>
<li>Product sales grew 11%, primarily driven by 14% volume growth. Excluding sales from the Horizon Therapeutics acquisition, product sales grew 10%, driven by 15% volume growth.</li>
<li>Ten products delivered at least double-digit sales growth in the fourth quarter, including Repatha (evolocumab), Blincyto (blinatumomab), Tezspire (tezepelumab-ekko), Evenity (romosozumab-aqqg) and Tavneos (avacopan).</li>
<li>The performance included $1.2 billion of sales from rare disease products, driven by several early-in-lifecycle medicines, including Tepezza (teprotumumab-trbw), Krystexxa (pegloticase), Uplinza (inebilizumab-cdon) and Tavneos.</li>
</ul>
Amgen reported adjusted EPS of $5.31, beating <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43477892/amgen-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">the consensus of $5.08</a>.
In its earnings release, the company said the FDA placed a clinical hold on its Phase 1 study of AMG 513 for obesity.
"Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong performance globally, we are investing heavily in our rapidly advancing pipeline to deliver innovative therapies across our four therapeutic areas," said&nbsp;Robert Bradway, chairman and chief executive officer.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43062677/fda-approves-amgen-treatment-for-pretreated-colorectal-cancer-with-certain-mutation" rel="noreferrer noopener">FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation</a>
Guidance: Amgen expects fiscal year 2025 revenue of $34.3 billion—$35.7 billion versus a consensus of $34.5 billion. The company expects adjusted EPS of $20-$21.20, compared to a consensus of $20.88.
Goldman Sachs is encouraged by the quarter and the company's growth prospects for 2025, which eases concerns about the stock.
Analyst Salveen Richter remains positive as the company continues to perform well, especially as investors recognize the value of MariTide in obesity and diabetes, along with upcoming approvals like Uplizna for IgG4-RD and gMG.
William Blair analyst Matt Phipps says the 2025 outlook mostly aligns with expectations, but R&amp;D spending and operating margin forecasts highlight ongoing investment in late-stage drugs, particularly MariTide and olpasiran.
William Blair analyst writes, "We believe continued growth of key assets, including Repatha, Tezspire, Evenity, Blincyto, and Imdelltra, combined with three biosimilar launches in 2025, will offset headwinds from biosimilar launches of Prolia and Xgeva, providing top-line growth combined with meaningful clinical readouts in 2025&#8230;"
Price Action: AMGN stock is up 5.41% at $304.65 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43498181/cdw-delivers-robust-q4-earnings-targets-continued-market-outperformance-in-2025" target="_blank" rel="noreferrer noopener">IT Company CDW Q4 Earnings: Sales Climb, AI Focus, Stock Buyback Boost &amp; More</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Earnings

Guidance

Movers

Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead

High-rolling investors have positioned themselves bullish on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in AMGN often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Amgen. This is not a typical pattern.
The sentiment among these major traders is split, with 66% bullish and 0% bearish. Among all the options we identified, there was one put, amounting to $25,560, and 8 calls, totaling $578,729.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $250.0 to $320.0 for Amgen during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 1031.71 with a total volume of 3,367.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $250.0 to $320.0 over the last 30 days.
<h3>Amgen 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738770325_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$21.0</td>
<td>$20.3</td>
<td>$20.81</td>
<td>$285.00</td>
<td>$252.8K</td>
<td>4.5K</td>
<td align="right">964</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$20.9</td>
<td>$20.25</td>
<td>$20.7</td>
<td>$285.00</td>
<td>$92.9K</td>
<td>4.5K</td>
<td align="right">365</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$10.7</td>
<td>$10.2</td>
<td>$10.25</td>
<td>$320.00</td>
<td>$58.4K</td>
<td>624</td>
<td align="right">462</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$10.9</td>
<td>$10.45</td>
<td>$10.7</td>
<td>$300.00</td>
<td>$53.5K</td>
<td>982</td>
<td align="right">249</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$21.25</td>
<td>$19.7</td>
<td>$20.8</td>
<td>$285.00</td>
<td>$35.3K</td>
<td>4.5K</td>
<td align="right">407</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
In light of the recent options history for Amgen, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Amgen</h3>
<ul>
<li>With a trading volume of 1,699,750, the price of AMGN is up by 5.44%, reaching $304.74.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 85 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Amgen</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $299.25.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Amgen, which currently sits at a price target of $280. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Hold rating for Amgen, targeting a price of $298. 
&#x2A; An analyst from Citigroup persists with their Neutral rating on Amgen, maintaining a target price of $295. 
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $324. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amgen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Amgen Options Trading: A Deep Dive into Market Sentiment

WIIM

Amgen shares are trading higher after the company on Tuesday reported Q4 financial results. The stock initially fell on the report but reversed on Wednesday.

Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) announced its Q4 earnings on Tuesday, February 4, 2025 at 04:01 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Amgen beat estimated earnings by 5.0%, reporting an EPS of $5.31 versus an estimate of $5.08.
Revenue was up $890.00 million from the same period last year.
<h3>Past Earnings Performance</h3>
In the previous quarter, the company beat on EPS by $0.47, resulting in a 1.0% increase change in the share price the following day.
Here's a look at Amgen's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>5.11</td>
<td>5</td>
<td>3.87</td>
<td>4.62</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>5.58</td>
<td>4.97</td>
<td>3.96</td>
<td>4.71</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>8.52B</td>
<td>8.33B</td>
<td>6.94B</td>
<td>8.13B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>8.50B</td>
<td>8.39B</td>
<td>7.45B</td>
<td>8.20B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Amgen <a href="https://www.benzinga.com/quote/AMGN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Amgen Earnings Report: Q4 Overview

Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) just disclosed its Q4 earnings on Tuesday, February 4, 2025 at 04:01 PM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Amgen beat estimated earnings by 5.0%, reporting an EPS of $5.31 versus an estimate of $5.08.
Revenue was up $890.00 million from the same period last year.
<h3>Overview of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.47, leading to a 1.0% increase share price change the next day.
Here's a look at Amgen's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>5.11</td>
<td>5</td>
<td>3.87</td>
<td>4.62</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>5.58</td>
<td>4.97</td>
<td>3.96</td>
<td>4.71</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>8.52B</td>
<td>8.33B</td>
<td>6.94B</td>
<td>8.13B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>8.50B</td>
<td>8.39B</td>
<td>7.45B</td>
<td>8.20B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Amgen <a href="https://www.benzinga.com/quote/AMGN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Summary: Amgen Q4

Press Releases

Asher Bio Announces Clinical Trial Collaboration and Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer

AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

deCODE genetics: Complete recombination map of the human-genome, a major step in genetics

AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

AMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE

AMGEN TO PRESENT AT CITI'S 2025 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT

GeminiBio Appoints Mike Stella to Board

Small Cap

Opinion

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

CELC

GNTA

ONCY

TSX:ONC

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Piper Sandler

B of A Securities

Citigroup

RBC Capital

Wells Fargo

시장이 불안정하고 혼란스러운 시기에는 많은 투자자들이 배당 수익률이 높은 주식으로 눈을 돌린다. 이러한 주식은 높은 잉여 현금 흐름을 가지고 있으며 주주들에게 높은 배당금을 지급하여 보상을 한다.
벤징가 독자들은 <a href="https://www.benzinga.com/analyst-stock-ratings">애널리스트 주식 등급</a> 페이지를 방문하여 자신이 선호하는 주식에 대한 최신 애널리스트 의견을 검토할 수 있다. 트레이더들은 벤징가의 방대한 애널리스트 등급 데이터베이스를 필터링하여 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">애널리스트 정확도</a>에 따라 정렬할 수 있다.
아래는 의료 부문에서 배당 수익률이 높은 세 개의 주식에 대한 가장 정확한 애널리스트들의 평가이다.
<h3 class="wp-block-heading">암젠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</h3>
<ul>
<li>배당 수익률: 3.67%</li>
<li>파이퍼 샌들러의애널리스트 데이비드 암셀렘(David Amsellem)은 1월 2일 주식에 대해 비중 확대 등급을 유지하고 목표 주가를 $344에서 $310으로 하향 조정했다. 이 애널리스트의 정확도는 66%이다.</li>
<li>BofA 증권의애널리스트 팀 앤더슨(Tim Anderson)은 12월 10일 주식에 대해 언더퍼폼 등급을 재부여하고 목표 주가를 $256로 설정했다. 이 애널리스트의 정확도는 63%이다.</li>
<li>최근 뉴스: 암젠은 12월 10일 1분기 배당금을 주당 $2.25에서 $2.38로 6% 인상했다.</li>
<li>Benzinga Pro의 실시간 뉴스 피드에서 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1">최신 AMGN 뉴스를</a> 알림 받았다.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-716759" style="width: 619px; height: auto;" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12.png" sizes="(max-width: 902px) 100vw, 902px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12-768x705.png 768w" alt="" width="902" height="828" /></a></figure>
<h3 class="wp-block-heading">애브비 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</h3>
<ul>
<li>배당 수익률: 3.66%</li>
<li>BofA 증권의애널리스트 팀 앤더슨(Tim Anderson)은 12월 10일 주식에 대해 중립 등급을 재부여하고 목표 주가를 $191로 설정했다. 이 애널리스트의 정확도는 63%이다.</li>
<li>리링크 파트너스의 애널리스트 데이비드 라이징거(David Risinger)는 11월 22일 주식을 시장 평균에서 아웃퍼폼으로 상향 조정하고 목표 주가를 $206으로 설정했다. 이 애널리스트의 정확도는 75%이다.</li>
<li>최근 뉴스: 애브비는 12월 13일 님블 테라퓨틱스(Nimble Therapeutics)를 인수할 계획을 발표했다.</li>
<li>Benzinga Pro의 실시간 뉴스 피드에서 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1">최신 ABBV 뉴스를</a> 알림 받았다.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-716760" style="width: 670px; height: auto;" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13.png" sizes="(max-width: 917px) 100vw, 917px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13-768x709.png 768w" alt="" width="917" height="847" /></a></figure>
<h3 class="wp-block-heading">CVS 헬스 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>배당 수익률: 6.02%</li>
<li>도이치 뱅크의 애널리스트 조지 힐(George Hill)은 12월 3일 주식을 보유에서 매수로 상향 조정하고 목표 주가를 $66으로 설정했다. 이 애널리스트의 정확도는 60%이다.</li>
<li>트루이스트 증권의 애널리스트 데이비드 맥도날드(David Macdonald)는 11월 20일 주식에 대해 매수 등급을 재확인하고 목표 주가를 $76에서 $67로 하향 조정했다. 이 애널리스트의 정확도는 63%이다.</li>
<li>최근 뉴스: 최근 법무부(DOJ)는 CVS가 2013년부터 불법 처방전으로 오피오이드 조합약과 과다량을 조제하여 관리 약물 법을 위반했다고 주장했다.</li>
<li>Benzinga Pro의 차트 도구가 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1">CVS 주식의 추세</a>를 식별하는 데 도움을 주었다.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-716761" style="width: 584px; height: auto;" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14.png" sizes="(max-width: 912px) 100vw, 912px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14-768x712.png 768w" alt="" width="912" height="845" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio">
<div class="wp-block-embed__wrapper"><iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&amp;feature=oembed" width="500" height="281" frameborder="0" allowfullscreen="allowfullscreen"></iframe></div>
</figure>
더 읽기:
<ul>
<li><a href="https://www.benzinga.com/25/01/42763645/how-to-earn-500-a-month-from-acuity-brands-stock-ahead-of-q1-earnings">애큐티 브랜드 주식으로 월 $500를 버는 방법</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

주식과 옵션을 볼 때 투자자들은 섹터 회전, 실적 강세, 다가오는 촉매제 등 여러 가지 전략을 사용한다. 가치 투자자들은 종종 <a href="https://www.benzinga.com/topic/dividend-stocks">배당주에서</a> 강력한 실적 강세를 찾는다.
다우존스 산업평균지수에는 배당금을 지급하는 주식이 많이 포함되어 있으며, 꾸준히 배당금을 인상해 온 블루칩 기업들이 많다.
2025년을 맞이하기 앞서, 다우존스의 고수익 주식들을 살펴보겠다.
무슨 일이 있었나: 다우존스 산업평균지수는 2025년 대통령 선거 이후 여러 주식 지수가 상승세를 보인 가운데 12월에 45,000으로 사상 최고치를 기록했다.
12월 27일 기준으로, 다우존스 산업평균지수의 주식 18개가 연초 대비 상승했으며, 12개 구성 종목은 2024년 초와 비교하여 하락세를 보이고 있다.
투자자들은 다우존스 산업평균지수 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)를 통해 전체 다우존스 산업평균지수에 투자할 수 있지만, 지수의 30개 구성 종목 중 개별 주식을 선택할 수도 있다. 12월 27일 기준으로 ETF는 연초 대비 13.4% 상승했다.
인기 있는 전략 중 하나는 &#8220;다우의 개(Dogs of the Dow)&#8221; 주식에 주목하는 것이며, 이는 종종 배당금 지급률이 높은 하락세를 보이는 주식과 일치한다.
&#x2A;&#x2A; 다우의 개: 다우존스 지수를 추종하는 강아지라는 의미.
2025년을 시작하기 위해 가장 높은 수익률을 기록한 다우존스 산업평균지수의 주식들이 아래와 같이 정리되어 있다. 배당 수익률과 2024년 주식 실적이 나열되어 있다.
<ol>
<li>버라이즌 커뮤니케이션스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>): 6.79% 수익률, 2024년 +5.9%</li>
<li>쉐브론 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>): 4.53% 수익률, 2024년 -3.5%</li>
<li>암젠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>): 3.62% 수익률, 2024년 -8.8%</li>
<li>존슨앤드존슨 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>): 3.42% 수익률, 2024년 -7.5%</li>
<li>머크 앤드 컴퍼니 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>): 3.25% 수익률, 2024년 -8.5%</li>
<li>코카콜라 컴퍼니 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): 3.11% 수익률, 2025년 +6.0%</li>
<li>IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>): 3% 수익률, 2024년 +36.2%</li>
<li>시스코 시스템즈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>): 2.68% 수익률, 2024년 +18.0%</li>
<li>맥도날드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>): 2.41% 수익률, 2024년 -1.0%</li>
<li>프록터 앤드 갬블 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>): 2.37% 수익률, 2024년 +15.7%</li>
</ol>
2025년을 맞이하여 가장 높은 수익률을 기록한 주식 10개 중 7개가 2024년 초에도 상위 10개 주식 목록에 올라 있었으며, 머크, 맥도날드 및 프록터 앤드 갬블이 새롭게 다우의 개 주식 목록에 오른 것으로 나타났다.
또한 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%97%94%EB%B9%84%EB%94%94%EC%95%84%EA%B0%80-%EB%8B%A4%EC%9A%B0%EC%A1%B4%EC%8A%A4-%EC%A7%80%EC%88%98%EC%97%90-%ED%95%A9%EB%A5%98-%EC%A7%80%EC%88%98%EC%97%90%EC%84%9C-%EC%96%B4%EB%96%A4-%EC%88%9C/" target="_blank" rel="noopener">엔비디아가 다우존스 산업평균지수에 포함된 것: 기술 대기업이 지수에서 차지하는 위치, 셔윈-윌리엄스 추가가 더 중요한 이유</a>
구성 변경이 수익률에 미치는 영향: 배당 투자자들은 그들이 익숙해진 높은 수익률의 주식들을 찾기 위해 다른 곳을 찾아야 할 것이다.
10.40%의 수익률을 제공하 월그린스 부츠 얼라이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)와 6.99%의 수익률을 주는 다우(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>)가 지수에서 교체되어 제외되었다.
2024년 새로운 다우존스 산업평균지수 구성 종목들은 높은 배당 수익률을 제공하지 않다. 셔윈-윌리엄스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>)는 0.80%의 배당 수익률, 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)는 0.03%의 배당 수익률, 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)은 배당금을 지급하지 않는다.
이는 다우존스 산업평균지수를 추적하는 ETF의 수익률이 낮아질 것을 의미하며, 과거 5년 동안 실적이 좋았던 주식으로 하락세를 보인 주식을 교체하여 더 강한 수익률을 추구하는 것이 목표이다.
최신 30개 다우존스 산업평균지수 구성 종목 중 28개 주식은 배당금을 지급하며, 아마존과 보잉(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)은 예외이다.
다우존스 산업평균지수의 평균 배당 수익률은 약 2%이다.
알고 계셨나요?
<ul>
<li>의회가 대규모 투자를 하고 있습니다.  <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent123024" target="_blank" rel="noreferrer noopener">2024년 선거를 앞두고 그들이 무엇을 사고 팔았는지 쉽게 확인할 수 있는 도구로 알아보세요</a></li>
</ul>
사진 출처: Shutterstock


다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

슈왑 미국 배당주 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>)는 12월에 7% 이상 하락하면서 지난 한 달 동안 1년간 상승폭의 절반 이상을 반납했다. <a href="https://www.benzinga.com/24/12/42528079/this-high-yield-dividend-etf-is-undergoing-a-harsh-reversal-signaling-bearish-trends-here-what-you-need-to-know" target="_blank" rel="noopener">SCHD 펀드가 하락한 이유를 살펴보자.</a>
알아야 할 내용: 슈왑 미국 배당주 ETF는 4개의 제약주가 펀드 전체 보유 자산의 15.83%를 차지해 헬스케어 부문에 큰 비중을 두고 있다. 헬스케어 섹터는 최근 도널드 트럼프 대통령 당선인의 행정부 책임자 임명 및 <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction" target="_blank" rel="noopener">정책 변화</a>에 대한 불확실성이 높아지면서 실적이 저조했다.
<h2>헬스케어 부문 보유 종목</h2>
브리스톨 마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)는 펀드 내에서 가장 큰 제약 보유 종목으로, 자산의 4.64%를 차지한다. 지난 한달 동안 주가는 2.6% 하락했다.
화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)도 펀드의 상위 10개 보유 종목에 속흔다. 백신 제조사 화이자는 앞으로 불확실한 정치 및 규제 환경에 직면하면서 대선 이후 5% 이상 하락했다.
애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)와 암젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)도 헬스케어 보유 종목이다. 애브비 주가는 소폭 하락했지만 암젠 주가는 12월에 체중 감량 약물 후보인 마리타이드(MariTide)의 실망스러운 <a href="https://www.benzinga.com/content/42377651/amgen-stock-falls-on-weight-loss-drug-data-overreaction-or-fair" target="_blank" rel="noopener">임상시험 </a>결과로 인해 10% 이상 하락했다.
금리: 슈왑 미국 배당주 ETF에 영향을 미칠 수 있는 또 다른 요인은 불확실한 금리 환경이다. 저금리 환경에서는 배당금이 투자자에게 더 매력적으로 다가오는 경향이 있다. 최근 연준의 발언에 따르면 인플레이션이 연준의 목표 금리인 2%를 상회하는 등 매파적인 전망이 나온다.
또한 트럼프가 해외 수입품에 대한 관세를 인상하겠다고 공약한 만큼 차기 트럼프 행정부가 인플레이션을 재점화하고 금리를 더 오래 유지할 수 있는 요인으로 작용할 수 있다.
금리가 높으면 채권 및 기타 채권형 증권의 수익률 경쟁이 치열해져 배당 수익률은 상대적으로 매력도가 떨어지게 된다.
이미지: Shutterstock
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%97%94%EB%B9%84%EB%94%94%EC%95%84-%EC%A3%BC%EA%B0%80-4-%EA%B0%80%EA%B9%8C%EC%9D%B4-%EC%83%81%EC%8A%B9%ED%95%9C-%EC%9D%B4%EC%9C%A0%EB%8A%94/" target="_blank" rel="noopener">엔비디아, 주가 4% 가까이 상승한 이유는?</a>
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)의 최근 주가가 하락세를 보이고 있다. 지난해 주가가 26.04% 상승했지만 <a href="https://www.benzinga.com/quote/LLY/news" target="_blank" rel="noopener" data-google-interstitial="false">최근 한 달 동안</a>에는 17.24% 하락했다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-658564" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM.png" sizes="(max-width: 628px) 100vw, 628px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM-300x234.png 300w" alt="" width="628" height="490" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1">차트: Benzinga Pro</a>
현재 일라이 릴리의 주가는 여름 고점에서 크게 하락하여 746.94달러에 거래되고 있다. 한 때 인기가 높았던 이 비만 치료제 제조사는 현재 하락세의 기술적 신호와 정치적 불확실성의 영향을 받고 있다.
이번 매도세가 과도한 반응일까?
추가 읽기: <a href="https://www.benzinga.com/24/11/42097813/eli-lilly-opts-to-develop-candidate-for-nervous-system-disease">일라이 릴리, 버지 지노믹스 ALS 약물 후보 개발 선택</a>
<h2 class="wp-block-heading">LLY 주식의 하락 신호</h2>
일라이 릴리의 주식은 8일, 20일  50일 지수 이동 평균선 이하로 거래되고 있어 확고한 하락세를 보이고 있다. 상대 강도 지수(RSI)는 33.02로 과매도 구역에 근접해 있으며, 이동평균 수렴발산(MACD)은 -37.55로 강한 하락 모멘텀을 확인해준다.
200일 단순 이동 평균인 835.76달러도 이제는 먼 기억이 되어 우려를 증폭시키고 있다.
<h2 class="wp-block-heading">케네디, 제약사 주가 하락의 원인</h2>
일라이 릴리와 함께 노보 노디스크 AS(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) 및 암젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)과 같은 반비만 약물 제조사들의 주가 하락은 대통령 당선이 도널드 트럼프가 로버트 F. 케네디 주니어를 보건복지부(HHS) 장관으로 임명할 가능성에 대한 우려로 연결되었다.
투자자들은 케네디의 GLP-1 체중 감소 치료제에 대한 비판적인 입장이 보험 적용 축소나 가격 압박으로 이어질 수 있다고 우려하고 있다. 해당 기관이 의회 없이 광범위한 변화를 시행할 수 있는 권한은 제한적이지만, 불확실성은 시장을 위축시켰다.
<h2 class="wp-block-heading">상승 가능성은?</h2>
반대 투자자들에게는 근본적인 요소들이 다른 그림을 보여준다. 일라이 릴리의 젭바운드(Zepbound) 및 마운자로(Mounjaro) 매출은 2026년까지 180억 달러에 이를 것으로 예상되며, 이는 2024년 추정치의 두 배이다.
총 매출은 2026년까지 690억 달러로 증가할 것으로 예상되며, 주당 순이익은 현재의 13.26달러의 두 배 이상인 30달러로 급증할 것으로 보인다.
그리고 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1">Benzinga Pro</a> 데이터에 따르면, 선행 주가수익비율(PER)이 33.2배인 반면, 주식 가치는 7월의 57.2배 고점보다 훨씬 매력적으로 보인다.
<h2 class="wp-block-heading">향후 전망</h2>
짐 크레이머의 의견은 반대론자의 감정을 요약해준다: &#8220;이 주식은 얼마 전만 해도 사랑받던 주식만큼이나 지금은 미움을 받고 있다. 나는 이것이 매수할 만하다고 생각한다&#8230; 매도는 충분하다.&#8221;
장기 투자자들에게는 일라이 릴리의 비만 약물 시장에서의 지배력이 여전히 매력적인 성장 이야기로 남아 있다.
매도세가 경고 신호인지 아니면 좋은 기회인지는 투자자들이 기본 요소에 얼마나 신뢰를 두고 있는지에 따라 달라질 수 있다.
주가 움직임: 일라이 릴리의 주식은 목요일 0.46% 하락한 749.92달러에 마감되었다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42097386/cvs-healthcignaunitedhealths-pharmacy-benefit-managers-accuse-ftc-of-overreach-in-effort-to-reshape-drug-rebate-system">대제약사 약제비 관리자가 약제 리베이트 제도 개편에 대한 FTC의 과도한 개입을 비난</a></li>
</ul>
사진 출처: Eli Lilly.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Long Ideas

Technicals

일라이 릴리의 주식은 케네디가 체중 감량 약물을 대상으로 하자 급락

CNN 머니 공포·탐욕 지수는 전반적인 시장 심리가 더 하락했음을 나타내면서 지난 금요일에 &#8216;중립&#8217; 영역으로 이동했다.
금요일(15일) 미국 증시는 다우존스 지수가 장중 300포인트 이상 하락하는 등 하락세로 마감했다. S&amp;P 500 지수는 주간 2.1%의 손실을 기록했고, 나스닥 종합 지수는 3.2% 정도 하락했다. 30개 종목으로 구성된 다우존스 지수는 한 주 동안 1.2% 하락했다.
주요 기술주들은 손실을 기록했으며, 특히 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 주가는 금요일에 3% 이상 하락했고, 마이크로소프트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) 주가는 세션 중 약 2.8% 하락했다. 그러나 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)는 금요일에 약 3% 상승했다.
제약주는 트럼프 대통령 당선인이 로버트 F. 케네디 주니어를 보건복지부(HHS) 장관으로 임명한 후 금요일 하락세로 마감했다. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) 주가는 7% 이상 하락했고 암젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) 주가도 4% 이상 하락했다. SPDR S&amp;P 바이오테크 ETF는 5% 이상 하락하며 2020년 이후 최악의 한 주를 기록했다.
경제 데이터 측면에서 10월 미국 수출 가격은 전월 대비 0.8% 상승했고, 10월 수입 가격은 전월 대비 0.3% 상승했다. 10월 미국 소매판매는 전월 대비 0.4% 증가하여 9월 수정치 0.8%보다는 하락했고, 시장 예상치 0.3%는 상회했다.
정보 기술, 통신 서비스, 헬스케어 섹터가 금요일에 가장 큰 손실을 기록하면서 S&amp;P 500의 대부분의 업종이 마이너스로 마감했다. 그러나 유틸리티와 금융 섹터는 전체 시장 추세와 다르게 상승세로 마감했다.
금요일 다우존스 지수는 약 306포인트 하락한 43,444.99포인트로 마감했다. S&amp;P 500 지수는 1.32% 하락한 5,870.62포인트, 나스닥 종합지수는 2.24% 하락한 18,680.12포인트로 마감했다.
투자자들은 오늘 트립닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>), 브래디 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRC#NYSE">BRC</a>), 에이컴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>)의 실적 발표를 기다리고 있다.
<h3>CNN 비즈니스 공포·탐욕 지수란? </h3>
CNN 공포·탐욕 지수는 현재 50.9를 기록하고 있다. 금요일에 &#8216;탐욕&#8217;에서 &#8216;중립&#8217; 영역으로 이동했으며, 이전 수치는 58.2였다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%9B%94%EC%9A%94%EC%9D%BC-%EC%A3%BC%EB%AA%A9%ED%95%B4%EC%95%BC-%ED%95%A0-%EC%A3%BC%EC%8B%9D-%EB%B8%8C%EB%9E%98%EB%94%94-%EC%97%90%EC%9D%B4%EC%BB%B4-it-%ED%85%8C%ED%81%AC-%ED%8C%A8%ED%82%A4/" target="_blank" rel="noopener">월요일 주목해야 할 주식: 브래디, 에이컴, IT 테크 패키징, 빗디어 및 트립닷컴</a>
사진 제공: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

MSFT

TCOM

TSLA

美 경제지표 발표, 엔비디아와 MS 주가 하락 후 다우 지수 300p 이상 하락: 공포·탐욕 지수는 '중립'

Comments

Amgen

뉴스

에 대한 최신 뉴스 Amgen (NASDAQ:AMGN) 주식

토요일, 1월 04, 2025

수요일, 1월 01, 2025

화요일, 12월 24, 2024

금요일, 11월 22, 2024

월요일, 11월 18, 2024

수요일, 11월 13, 2024

금요일, 10월 11, 2024

일요일, 7월 07, 2024

목요일, 7월 04, 2024

월요일, 5월 06, 2024

금요일, 5월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌